Medincell Stock Drops Over 2%, Marks a Second Session in the Red
The biotech company from Montpellier continues its decline in early afternoon, contrary to a nearly flat SBF 120. The stock remains stuck at the lower end of the broader index, amid a market environment characterized by renewed tensions in the Middle East and firm Brent prices. Technical analysis shows the stock has returned to its short-term moving average.
A Decline Pushes Medincell to the Bottom of the SBF 120, Contrasting with the CAC 40
Medincell's stock drops 2.3% to €27.20, while the SBF 120 remains stable (+0.05%) and the CAC 40 is stagnant at 8,328.56 points. The stock is among the largest declines in the broader index, extending the slide described in the previous session. Over a week, the stock has lost nearly 7.5%, barely dampening its more than 18% gain over three months and 71% over a year. Meanwhile, the VIX relaxes to 15.99, down 5.4%.
A Stock Returns to its 20-Day Moving Average Following Annual Account Publication
At €27.20, the stock is at its 20-day moving average (€27.11), which it fails to turn into a solid support, while the 50-day moving average (€26.98) and the 200-day moving average (€26.50) remain below the price, marking the potential landing zone in case of further decline. The RSI at 53 is neutral, signaling neither buying pressure nor seller fatigue, reflecting a digestion phase after the volatility of June. The decline follows the shock of the annual results published on June 16, which highlighted a 42% jump in Uzedy royalties to €9.3M but a widened net loss to €31.3M.
During this June 16, 2026 publication, the company also confirmed its target to commercially launch Olanzapine LAI in Q4 2026, identified as the next milestone for the project. The support at €24.08 remains the identified lower boundary by indicators, while the resistance at €29.56, tested unsuccessfully in early July, still caps any rebound attempts.
